Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $95 from $65 and keeps a Neutral rating on the shares. The firm updated its model following the Q4 earnings report and notes that management expects to opt-out of the 50/50 profit and loss sharing arrangement for rusfertide with Takeda (TAK) in Q2.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
- Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
- Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan
- Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
- Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen